Tag: Cognito Therapeutics

Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease

Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease

Financing positions company for pivotal study data readout, FDA submission, and 2027 commercialization in Alzheimer’s disease CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced the…

Read More Read More

Cognito Therapeutics has filed a notice of an exempt offering of securities to raise $60,032,626.00 in New Equity Investment.

Cognito Therapeutics has filed a notice of an exempt offering of securities to raise $60,032,626.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Cognito Therapeutics is raising up to $60,032,626.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Brent Vaughan played a…

Read More Read More

Cambridge Massachusetts based Cognito Therapeutics is raising $126,175,917.00 in New Equity Investment.

Cambridge Massachusetts based Cognito Therapeutics is raising $126,175,917.00 in New Equity Investment.

Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Cognito Therapeutics is raising $126,175,917.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brent Vaughan played a…

Read More Read More